What happened
A July 21 review in the Journal of Bone and Joint Surgery maps peptide applications across orthopaedics, from approved hormone-derived drugs to antimicrobial candidates and engineered delivery systems. The field combines mature therapies with a much larger preclinical pipeline.
What the review found
Teriparatide, a synthetic parathyroid-hormone-derived peptide, is an established bone-active medicine. PLG0206 is an engineered antimicrobial peptide being studied for difficult biofilm-associated infections. Other candidates aim to penetrate cartilage or release locally over time, while artificial-intelligence design is expanding the number of sequences that can be proposed.
Evidence check
A narrative clinical review organizes a mixed evidence base; it does not make every platform equally validated. The authors note that no peptide-based disease-modifying osteoarthritis drug has achieved clinical validation. Approved use for one peptide cannot be generalized to compounded or experimental products marketed for injury recovery.
Why it matters
Orthopaedics highlights both sides of peptide medicine: proven endocrine pharmacology and attractive but unconfirmed regeneration claims. Readers should ask which exact molecule, indication, formulation and trial supports a claim. The category name “peptide” is not itself evidence.
The source ledger and revision history are retained with the newsroom record.
Codex assisted with source organization and drafting. Vitalspan Wire is accountable for the published text and maintains a revision record.
This article provides general information, not diagnosis or treatment advice. Consult a qualified clinician before making medical decisions.